What is standard, first-line therapy for men with mHSPC today?

A presentation at the ongoing annual meeting of the European  Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Adding ADT to radiation therapy may carry increased cardiovascular risk

Some recent randomized clinical trials have shown that adding androgen deprivation therapy (ADT) to radiation therapy can improve outcomes in some circumstances. However, … READ MORE …

ADT and radiation for first-line treatment of node-positive (N1) prostate cancer

It’s now a relatively rare occurrence (about 12 percent of new patients) to be newly diagnosed with pelvic lymph node positive (N1) prostate cancer. Traditionally, this had been treated with ADT only because radiation therapy (RT) was thought to be of no benefit in extending survival. … READ MORE …

IADT, dutasteride, and the AVIAS trial — not the result some would want to hear

So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …

Two different “takes” from the results of the CHAARTED trial

In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …

Resistance training and quality of life among men on ADT

A newly published study has added to the mounting evidence that resistance training and related exercises are a valuable complement to medical care for men on androgen deprivation therapy (ADT). … READ MORE …

15-year survival and related data after first-line brachytherapy

Stone, Stock, and colleagues at the Icahn School of Medicine at Mount Sinai, New York, have been treating prostate cancer patients with brachytherapy since 1990 and (to whatever extent was possible) maintaining meticulous records throughout that time period. … READ MORE …